Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Study of the Safety and Clinical Proof-of-Concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome

Next Previous
X
Search
Trial Profile

A Phase IIa Study of the Safety and Clinical Proof-of-Concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors BELLUS Health

    • Most Recent Events

    • 23 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 04 May 2010 The primary endpoint of this proof-of-concept trial was not met, according to a BELLUS Health media release. As a result, BELLUS have announced that they are discontinuing the development of NC 503 for type 2 diabetes mellitus.
    • 15 Apr 2008 Interim results are expected in late 2008 or early 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top